AlzGene - Gene overview of all published AD-association studies for ACE
Back Search Methods Disclaimer Credits
 Gene: ACE  (DCP; DCP1; CD143; MGC26566; ACE1)  Entrez Gene    View on ALSGene   View on MSGene   View on PDGene   View on SZGene
 Protein: angiotensin I converting enzyme (peptidyl-dipeptidase A) 1   ProteinLink
 Chromosome: 17   (View: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  X  Y  MT)
 Status: Updated 18 April 2011
Meta-Analysis
1. Case-Control Studies (by ethnic group)
      AD Cases Normal Controls    
Study Population Source # Polys # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Alvarez, 1999
Spain CL  1  (detail)  350
(56%)
C-72 + 9
(-)
517
(-)
-Positive
Blomqvist, 2005
Overlaps with
Kehoe, 2003
CL  7  (detail)  ------n.a.
Blomqvist, 2005
Overlaps with
Kehoe, 2003
CL  7  (detail)  ------n.a.
Bruandet, 2008
France CO  2  (detail)  141
(60%)
C-78.7 + 5.8
(-)
6467
(61%)
73.8 + 5.3
(-)
Negative
Buss, 2002
Europe (mixed) CL  1  (detail)  261
(75%)
C-75.5 + 8.8
(-)
306
(60%)
67.9 + 12.5
(-)
Negative
Carbonell, 2003
UK CL  1  (detail)  80
(-)
C-79
(-)
65
(-)
75
(-)
Negative
Chalmers, 2004
Overlaps with
Kehoe, 2003
CL  1  (detail)  ------n.a.
Chapman, 1998
Israel CL  1  (detail)  49
(-)
C74.8 + 9.7
(-)
-40
(-)
72.7 + 7.8
(-)
Negative
Corder, 2006
Overlaps with
Lehmann, 2005
CL  1  (detail)  315
(-)
M--260
(-)
-n.a.
Corder, 2008
Overlaps with
Kehoe, 2003
CL  6  (detail)  938
(-)
U--397
(-)
-n.a.
Corneveaux, 2010
USA, UK & Netherlands (TGEN) CL  1  (detail)  1019
(64%)
N--591
(48%)
-n.a.
Cousin, 2009
France CL  2  (detail)  428
(-)
C64.9 + 9.9
(-)
-475
(-)
66.2 + 10.8
(-)
Negative
Edwards, 2009
USA CL  8  (detail)  296
(-)
M71.7 + 7.8
(-)
79 + 6.6
(-)
566
(-)
73.6 + 6.3
(-)
Positive
Farrer, 2000
USA, Canada & Italy CL  1  (detail)  236
(-)
U75.2 + 7.6
(52-94)
-169
(-)
70.2 + 10.2
(38-96)
Trend
Farrer, 2000
Russia CL  1  (detail)  150
(-)
U64.6 + 8.8
(40-88)
-206
(-)
64.9 + 11.4
(40-91)
Trend
Feulner, 2009
Germany CL  14  (detail)  491
(57%)
C-72.2
(-)
479
(46%)
39.5
(-)
Negative
Ghebranious, 2010
USA (PMRP) PO  4  (detail)  153
(60%)
C-78.2 + 6.4
(-)
302
(66%)
87.2 + 3
(-)
Positive
Giedraitis, 2009
Sweden (ULSAM) CL  9  (detail)  86
(0%)
C80.2
(72-85)
-404
(0%)
81.8
(80-84)
Negative
Helbecque, 2009
Overlaps with
Richard, 2001
CL  3  (detail)  376
(64%)
C-75 + 5
(-)
444
(64%)
74 + 8
(-)
Positive
Isbir, 2000
Turkey CL  1  (detail)  35
(74%)
C-73.9 + 7.4
(-)
29
(31%)
73.6 + 13.6
(-)
Trend
Isbir, 2001
Same as Isbir, 2000 CL  1  (detail)  ------n.a.
Katzov, 2004
Overlaps with
Kehoe, 2003
CL  3  (detail)  ------n.a.
Kehoe, 1999
Ireland CL  1  (detail)  209
(-)
U76.6 + 6.4
(-)
-198
(-)
77.1 + 6.4
(-)
Positive
Kehoe, 1999
UK (London) CL  1  (detail)  135
(-)
U82.3 + 6.7
(-)
-111
(-)
80.8 + 4.5
(-)
Positive
Kehoe, 1999
UK (Cardiff) CL  1  (detail)  198
(-)
U70.3 + 9.4
(-)
-77
(-)
73.5 + 6.2
(-)
Positive
Kehoe, 2003
Sweden (Set A) CL  7  (detail)  204
(61%)
M71.8 + 8.6
(-)
77.5 + 8.2
(-)
185
(58%)
73.4 + 9.6
(-)
Positive
Kehoe, 2003
Scotland (Set B) CL  7  (detail)  121
(58%)
M52.4 + 6.8
(-)
57.8 + 6.3
(-)
152
(38%)
58.2 + 9.8
(-)
Positive
Kehoe, 2003
Sweden (Set C) CL  3  (detail)  186
(52%)
M72.8 + 7.6
(-)
76.2 + 6.8
(-)
326
(66%)
83.6 + 3.2
(-)
Positive
Kehoe, 2003
UK (Set D) CL  4  (detail)  335
(60%)
M72.9 + 9.2
(-)
80.7 + 8
(-)
110
(46%)
77.1 + 9.1
(-)
Positive
Koelsch, 2005
Germany CL  1  (detail)  351
(68%)
C-72.9 + 9.1
(-)
348
(53%)
72.5 + 7.3
(-)
Positive
Lehmann, 2005
UK CL  1  (detail)  203
(57%)
M70.5 + 9.1
(-)
-248
(52%)
76.1 + 9.2
(-)
Negative
Lendon, 2002
UK CL  1  (detail)  214
(54%)
N61.3 + 9.2
(40-84)
-99
(-)
-Negative
Li, 2008
Canada CL  3  (detail)  753
(58%)
C71.9 + 8.5
(-)
77.8 + 8.6
(-)
736
(64%)
73.4 + 7.9
(-)
Trend
Mattila, 2000
Finland CL  1  (detail)  80
(64%)
M--67
(45%)
75.9 + 7.3
(-)
Positive
Miners, 2009
Overlaps with
Kehoe, 2003
CL  4  (detail)  101
(59%)
M-79.3 + 9.6
(-)
51
(65%)
77.7 + 10.8
(-)
n.a.
Monastero, 2002
Italy CL  1  (detail)  149
(65%)
C69.7 + 7.7
(50-85)
72 + 9.7
(51-89)
149
(-)
73.3 + 7.6
(-)
Negative
Myllykangas, 2000
Finland PO  1  (detail)  121
(87%)
N-92.2 + 3.1
(-)
75
(83%)
92.3 + 3.8
(-)
Negative
Nacmias, 2006
Italy CL  1  (detail)  388
(61%)
C68.5 + 7
(-)
-303
(65%)
90.9 + 12.5
(-)
Negative
Narain, 2000
UK CL  1  (detail)  239
(64%)
N-81.2 + 7.8
(-)
342
(59%)
82.1 + 3.8
(-)
Positive
Palumbo, 1999
Italy CL  1  (detail)  140
(63%)
C70.4 + 5.9
(-)
74.3 + 6.2
(-)
40
(70%)
71 + 4
(-)
Negative
Panza, 2002
Italy CL  1  (detail)  141
(-)
U--268
(-)
-Negative
Panza, 2003
Same as Panza, 2002 CL  1  (detail)  ------n.a.
Prince, 2001
Sweden CL  1  (detail)  204
(61%)
M--186
(58%)
-Negative
Reiman, 2007
Overlaps with
Corneveaux, 2010
CL  3  (detail)  861
(-)
M-74.9 + 6.6
(-)
550
(-)
77.4 + 7.3
(-)
Negative
Richard, 2001
France (I) CL  1  (detail)  433
(64%)
C73 + 5
(-)
75 + 6
(-)
475
(66%)
75 + 8
(-)
Positive
Richard, 2001
France (II) CL  1  (detail)  56
(-)
C-85 + 6
(-)
221
(76%)
-Positive
Sarajarvi, 2010
Finland CL  1  (detail)  642
(68%)
C71 + 7
(43-89)
-682
(60%)
69 + 6
(37-87)
Negative
Scacchi, 1998
Italy CL  1  (detail)  80
(71%)
C-83.5 + 5.9
(-)
155
(77%)
78.3 + 7
(-)
Negative
Seripa, 2003
Italy CL  1  (detail)  126
(59%)
C7.2
(-)
69.3 + 7
(53-84)
106
(50%)
62.4 + 10.5
(42-86)
Negative
Seripa, 2003
USA CL  1  (detail)  124
(54%)
N71.7 + 8.5
(-)
80.9 + 7.6
(64-98)
97
(53%)
84 + 8.6
(65-101)
Negative
Sherbatykh, 2001
Same as Farrer, 2000 (Russian) CL  1  (detail)  ------n.a.
Shulman, 2010
USA CO  1  (detail)  173
(-)
C--131
(-)
-Negative
Sleegers, 2005
Netherlands PO  1  (detail)  250
(71%)
U-82 + 7.3
(-)
6153
(-)
-Trend
Thornton-Wells, 2008
Re-analysis of Edwards, 2009 CL  0  451
(-)
M--699
(-)
-n.a.
Trebunova, 2008
Slovakia CL  1  (detail)  70
(56%)
C-73 + 12
(-)
126
(50%)
72 + 14
(-)
Negative 
Webster, 2010
Overlaps with
Corneveaux, 2010
CL  1  (detail)  861
(-)
M-82.8 + 7.7
(-)
550
(-)
79.7 + 6.3
(-)
n.a. 
Webster, 2010
Germany CL  1  (detail)  200
(73%)
C73 + 7.1
(-)
76 + 6.5
(-)
126
(51%)
73 + 6.4
(-)
Positive 
Wehr, 2006
Poland CL  1  (detail)  100
(66%)
C-71.8 + 7.9
(52-91)
144
(53%)
70.5 + 8.8
(47-93)
Negative
Zuiliani, 2001
Italy CL  1  (detail)  40
(70%)
C-79.2 + 1
(-)
54
(67%)
82.1 + 0.8
(-)
Negative
 Asian
Cheng, 2002
China CL  1  (detail)  173
(44%)
C-74.3 + 6.4
(-)
285
(49%)
53.9 + 8.2
(-)
Positive
Hu, 1999
Japan CL  1  (detail)  132
(-)
C-73.7 + 11
(-)
257
(-)
58.4 + 22
(-)
Positive
Ning, 2010
China CL  3  (detail)  144
(58%)
C-71.6 + 7.3
(-)
476
(64%)
69.3 + 8.7
(-)
Positive
Wakutani, 2002
Japan CL  1  (detail)  241
(-)
U--352
(-)
-Negative
Wang, 2006
Taiwan CL  2  (detail)  151
(59%)
C-74.8 + 7.9
(-)
161
(47%)
62.5 + 8.7
(-)
Positive
Wang, 2007
China CL  1  (detail)  104
(46%)
C-79.2 + 6.3
(64-97)
128
(30%)
68.1 + 2.8
(65-77)
Positive
Wang, 2010
China (XWH) CL  11  (detail)  237
(57%)
C69 + 8.9
(-)
72.6 + 8.9
(-)
234
(60%)
71.9 + 8.4
(-)
Negative
Yang, 2000
Overlaps with
Ning, 2010
CL  1  (detail)  188
(60%)
C70
(-)
74.6 + 8.9
(-)
227
(49%)
74.2 + 8.3
(-)
n.a.
Zhang, 2005
China CL,PO  1  (detail)  192
(51%)
C68.9 + 9.3
(45-92)
-195
(45%)
70 + 7.8
(48-90)
Trend
 Hispanic
Camelo, 2004
Colombia CL  1  (detail)  83
(72%)
C68.3 + 5
(-)
69 + 8.9
(-)
69
(72%)
71.4 + 12.3
(-)
Negative
 Other/Mixed
Bowirrat, 2005
Overlaps with
Meng, 2006
CO  1  (detail)  85
(-)
C--112
(-)
-n.a.
Crawford, 2000
USA CL,CO  1  (detail)  171
(58%)
C--175
(66%)
-Positive
Keikhaee, 2006
Iran CL  1  (detail)  117
(52%)
C-73.6 + 6.3
(-)
125
(59%)
69.8 + 6.2
(-)
Negative
Meng, 2006
Israel CO  12  (detail)  92
(180%)
C--166
(-)
-Positive
Perry, 2001
USA CL  1  (detail)  111
(69%)
M70.8 + 7.8
(-)
71.3 + 7.7
(-)
78
(76%)
75.2 + 7.6
(-)
Negative
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
2. Family-Based Studies (by ethnic group)
      Affecteds Unaffecteds    
Study Population # Polys # Families # Subjects
(% women)
DX Onset Age
(range)
Age
(range)
# Subjects
(% women)
Age
(range)
Result Comment
 Caucasian
Edwards, 2009
USA (CAP, NIMH, IU)  8  (detail)  738-M72.3 + 9.1
(-)
74.8 + 11
(-)
--Positive
Thornton-Wells, 2008
Re-analysis of Edwards, 2009  0  6541422
(-)
M--744
(-)
-n.a.
 Other/Mixed
Schjeide, 2009
USA (CAG)  3  (detail)  217222
(59%)
M69.2 + 9
(50-89)
-267
(63%)
72.9 + 8.8
(49-92)
Negative
Schjeide, 2009
USA (NCRAD)  3  (detail)  340741
(74%)
M71.3 + 7.6
(50-98)
-300
(55%)
71 + 8.4
(39-93)
Negative
Schjeide, 2009
USA (NIA)  3  (detail)  351803
(64%)
M74.1 + 7.1
(52-98)
-290
(59%)
73.3 + 9.5
(36-94)
Negative
Schjeide, 2009
USA (NIMH)  3  (detail)  436995
(74%)
M72.4 + 7.7
(50-97)
-411
(58%)
70 + 10.7
(31-93)
Positive
Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.
Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis ->  "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.
AlzGene Recent Updates
AlzGene Top Results
AlzGene Stats
Studies: 1395
Genes: 695
Polymorphisms: 2973
Meta-analyses: 320
Cure Alzheimer's Fund
Proud supporter of the AlzGene database.
Michael J. Fox Foundation
The PDGene database is supported by a grant from The Michael J. Fox Foundation in partnership with the Alzheimer Research Forum.

NCRAD

The National Cell Repository for Alzheimer Disease seeks to recruit 1,000 families with two or more living brothers or sisters who have been diagnosed with late onset Alzheimer’s disease.
ALSGene
AlzGene
MSGene
PDGene
SZGene
An up-to-date collection of all published genetic association studies.